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Background: This study investigated postoperative morbidity, mortality, and the
long-term survival for patients with lung cancer who have interstitial lung diseases.
Methods: A retrospective chart review of 931 patients with lung cancer who
underwent pulmonary resection at Chiba University Hospital between 1990 and
2000 was undertaken. Interstitial lung disease was defined by medical history,
physical examination, and abnormalities compatible with bilateral lung fibrosis on
chest computed tomography or high-resolution computed tomography (36 patients:
3.9%, interstitial lung diseases group). The remaining 895 patients (96.1%) were
categorized as non–interstitial lung disease group.
Results: The incidence of postoperative pneumonia and acute or exacerbation of
interstitial pneumonia was higher in the interstitial lung disease group (all P  .05).
Thirty-day mortality was statistically equivalent between the interstitial lung disease
and the non–interstitial lung disease groups (P  .30). The 5-year overall survivals
were 62.5% (non–interstitial lung disease) and 35.6% (interstitial lung disease).
Respiratory failure was the second main cause of death after the recurrence of
primary cancer in the interstitial lung disease group. The risk factors for long-term
mortality were interstitial lung diseases, advanced pathologic stage, male sex, high
age, and positive smoking history (all P  .05).
Conclusions: Interstitial lung disease was a risk factor for developing postoperative
morbidity and mortality and poor long-term survival due to the occurrence of
respiratory failure.
Interstitial lung disease (ILD), such as idiopathic pulmonary fibrosis (IPF),interstitial pneumonia due to collagen vascular diseases, and occupationallung diseases, have been widely known to be associated with lung cancer.Several environmental hazards, such as cigarette smoking and occupationalexposures, are proposed as common risk factors for ILD.1,2 When suchILDs are associated with lung cancer, the existence of ILD becomes an
obstacle for surgical treatment due to high postoperative pulmonary complications
and mortality. However, the influences of the existence of ILD as a complication on
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morbidity, mortality, and long-term survival after pulmo-
nary resection for lung cancer has not been well studied.
Therefore, the purpose of this study was to identify the
incidence of postoperative complications and mortality after
lung cancer surgery in the presence of ILD and to clarify the
impact of preoperative existence of ILD on the long-term
survival after pulmonary resection for lung cancer.
Patients and Methods
Patients
The medical records of 931 consecutive patients with lung cancer
who underwent pulmonary resection between January 1990 and
March 2000 at Chiba University Hospital were retrospectively
reviewed. Data were collected from our institutional cancer regis-
try database and from patient follow-up visits in the physician’s
office. The records contain detailed preoperative patient character-
istics, disease status, operative procedures, postoperative compli-
cations, pathologic diagnosis, neoadjuvant and adjuvant therapies,
and follow-up data. These data were collected at the time of
hospital discharge and from outpatient charts in a prospective
basis. Preoperative chest conventional or high-resolution com-
puted tomography (HRCT) was evaluated to examine not only the
extent of cancer but also the existence of ILD in all cases. ILD was
defined by medical history, physical examination, and abnormal-
ities compatible with bilateral lung fibrosis on chest computed
tomography (CT) or HRCT, such as peripheral reticular opacities.
When the chest CT, reviewed by radiologists, revealed such ab-
normalities, patients were referred to pulmonologists and the ex-
istence of ILD was evaluated preoperatively. Non-ILD and ILD
groups consisted of 895 (96.1%) and 36 (3.9%) patients, respec-
tively, of all enrolled patients. The ILD group included 26 patients
with IPF, 5 with pneumoconiosis, and 5 with connective tissue
diseases (4 rheumatoid arthritis and 1 Sjo¨gren syndrome). Three
patients received steroid therapy before operation. Patients with
severely symptomatic ILD who had diffuse IP on chest CT were
usually judged inoperable. All identified IPF patients showed
radiologically localized changes, which were restricted in the
bilateral lung basal segmental areas or lower lobes and confirmed
by chest CT.
Preoperative evaluation for all patients otherwise included a
detailed medical history, physical examination, blood and urine
examinations, and a 12-lead electrocardiogram. Incentive spirom-
etry and nebulizing by distilled water with or without bronchodi-
lator were routinely encouraged for enhancing lung expansion and
airway clearance at least for 2 weeks before and after surgery.
Neoadjuvant or adjuvant therapy, which was platinum agent–
based chemotherapy and radiation, was performed mainly for the
patients who had locally advanced disease or multiple nodal in-
volvement, or who underwent incomplete resection. The postop-
erative morbidities included bacterial pneumonia (confirmed by
infiltrative shadows on chest radiograph, positive sputum culture,
body temperature 37.5°C, and white blood cell count 10,000/
L), interstitial pneumonia (aggravation of dyspnea on exertion,
deterioration of arterial blood gas analysis, and diffuse interstitial
abnormalities compatible with acute interstitial pneumonia [AIP]
in the non-ILD group or exacerbation of IP in the ILD group on
chest radiograph and CT), mechanical ventilation for more than 3
days, bronchial stump dehiscence, empyema (positive bacterial
infection of pleural effusion), tracheostomy (scheduled at the time
of operation and postoperative emergency procedure), and post-
operative home oxygen therapy (HOT) for patients with PaO2 less
than 55 mm Hg at rest or less than 60 mm Hg on exercise at the
time of hospital discharge.
After discharge from the hospital, patients visited our outpa-
tient clinic regularly every 1 to 6 months, unless tumor recurred or
the patient had any health problems. When patients returned to the
referral doctors or were introduced to other doctors, the patients’
condition and causes of death (if patients died) were confirmed by
mail or telephone to the patient, patient’s family, or referral doc-
tors every 2 years. The follow-up was completed in 908 of 931
patients through March 2001 (with loss of follow-up data of 23
non-ILD patient) and the median follow-up was 43.8 months. The
overall survival was analyzed for each group of the patients.
Statistical Analysis
Data were analyzed with StatView version 5.0 software (Statistical
Analysis Systems; Cary, NC). To compare the differences between
the ILD and non-ILD groups, a Mann-Whitney U test was used to
analyze for continuous variables, and the 2-square test or Fisher
exact test to analyze for categorical variables. The survival curves
were estimated with the Kaplan-Meier method, and the difference
in survival times between the 2 groups was calculated by the
log-rank test. The Cox proportional hazard model was conducted
for identifying prognostic factors.
Results
Preoperative Patient Characteristics
Preoperative patient characteristics are summarized in Table
1. Male sex was more predominant in the ILD group than in
the non-ILD. Although smoking history was significantly
more prevalent in the ILD than the non-ILD (P  .001),
smoking index was not statistically significant between the
2 groups. Comparing pulmonary function tests and arterial
blood gas values between the 2 groups, percent forced vital
capacity (%FVC), forced expiratory volume in 1 second
(FEV1), % predicted FEV1, and FEV1/FVC in patients with
ILD were significantly lower than those in patients without
ILD. There were similar number of patients who received
neoadjuvant chemotherapy or radiation therapy between the
2 groups.
Perioperative characteristics are listed in Table 2. Pneu-
monectomy was not performed in the ILD group. Because
tumor size was relatively large (maximal diameter: 4.5 
2.7 cm) and pulmonary function was preserved in the ILD
group, limited pulmonary resection (segmentectomy or par-
tial lung resection) was not a preferred method compared
with the non-ILD group. Therefore, the selection of opera-
tive methods was similar between the groups. The distribu-
tions of histologic types and pathologic stages were also
similar between the 2 groups. There were no differences in
the number of adjuvant treatments between the 2 groups.
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Postoperative Morbidity and Mortality
Postoperative pulmonary complications and mortality are
summarized in Table 3. The frequencies of all specific
pulmonary complications were significantly higher in the
patients with ILD as compared with the patients without
ILD. In particular, 27 patients had postoperative AIP in the
non-ILD group or deterioration of IP in the ILD group. The
incidence in the ILD group was significantly higher than
that in the non-ILD group (P  .0001). Although they
received postoperative steroid pulse therapy (intravenous
injection of methylprednisolone 0.5 to 1 g for 3 days) or
high dose of prednisone (30 to 60 mg/d), 4 patients (1 in the
non-ILD and 3 in the ILD) died of uncontrollable IP in
hospital. Thirty-day mortality in patients with ILD was
equivalent to that of patients without ILD (P  .30). The
causes of 30-day mortality in the non-ILD group were as
follows: empyema with bronchial fistula, 2; bacterial pneu-
monia, 1; interstitial pneumonia, 1; empyema, 1; myocar-
dial infarction, 1; massive bleeding, 1; and brain infarction,
1. Deterioration of IP was observed in 1 case in the ILD
group.
Survival Analyses
Figure 1 shows overall survival after the the surgery. The
cumulative survivals at 3 and 5 years were 71.0% and
62.5% in the non-ILD group and 41.5% and 35.6% in the
ILD group, respectively (P  .0001).
The causes of deaths are shown in Table 4. Respiratory
failure due to bacterial pneumonia, AIP, and deterioration of
IP was the second most frequent cause of death after the
recurrence of primary cancer in the ILD group (33.3%) and
was seen in a higher proportion in the ILD group than in the
non-ILD group (P  .0028). The investigation of long-term
respiratory complications in 35 patients with ILD who sur-
vived more than 30 days revealed that 7 patients had im-
mediate deterioration of IP. Two of them died between 30
and 60 days and 5 patients gradually progressed. One pa-
tient had bacterial pneumonia with bronchial fistula and
died at the 33 days postoperatively. In 4 patients, a gradual
progression of fibrosis was seen, despite no initial change of
IP. One patient had no deterioration of IP but frequent
pneumonia. There were no changes in the respiratory con-
dition in 22 patients (22/35, 62.9%) during the observation
period.
We also attempted to clarify risk factors for long-term
overall mortality (Table 5). ILD, male sex, higher age,
positive smoking history, and pathologic stages III and IV
(all P  .05) were identified as independent risk factors
according to Cox’s proportional hazard model.
Discussion
It has been reported that ILD including IPF, asbestosis, and
silicosis are associated with a high risk of lung cancer.1,3
Common characteristics of these diseases are male sex, high
age, and heavy cigarette smoking. As these patients have
pulmonary impairment and poor reserve of cardiopulmo-
nary function, many patients do not match operative indi-
cations and need palliative care. In our study, lung cancer
with ILD was significantly more frequently found in men
and those with positive smoking history.
Although pulmonary function was significantly lower in
the ILD group, the PFT data showed that patients had
enough pulmonary reserve for operation. Flaherty and Mar-
tinez4 reported that pulmonary function testing can provide
an estimate of histologic severity but not a definitive quan-
tification of histologic fibrosis or inflammation. Martinod
and colleagues5 reported pulmonary functions of 20 ILD
patients who underwent pulmonary resection for lung can-
cer. They had well-preserved pulmonary functions similar
to our results. Doherty and coworkers6reported that heavy
smoking patients with IPF (most of them were men) tended
to preserve lung volumes and that emphysema due to smok-
ing could explain the relative volume preservation. In this
study, IPF or IP due to collagen vascular diseases were
limited in the basal segments or lower lobes preoperatively,
and patients with ILD had higher prevalence rate of positive
smoking history than those without ILD. This may be one of
the reasons for FEV1/FVC reduction due to emphysematous
change. Therefore, it is believed that PFT did not reflect the
severity of ILD.
ILD had an adverse effect on short- and long-term sur-
vivals. Postoperative deterioration of IP necessitating me-
TABLE 1. Preoperative characteristics of lung cancer pa-
tients
Characteristics
Non-ILD
(n  895)
ILD
(n  36) P value
Gender
Male 599 (66.9%) 32 (88.9%) .006
Female 296 4
Age (year)* 63.1 10.1 65.5 7.0 .200
BMI (kg/m2)* 22.2 3.0 21.5 2.7 .280
PSH (%) 614 (68.6%) 35 (97.2%) .0001
Smoking index* (pack-
year)
33.6 33.0 49.7 25.2 .216
Pulmonary function tests*
FVC (L) 2.95 0.74 2.74 0.61 .1759
%FVC (%) 97.3 17.3 84.9 17.4 .0001
FEV1 (L) 2.22 0.59 1.96 0.52 .0136
%FEV1 (%) 84.4 18.8 68.7 17.1 .0001
FEV1/FVC (%) 75.9 9.8 70.8 12.8 .0191
PaO2 (mm Hg) 87.8 9.6 85.4 9.8 .0910
PaCO2 (mm Hg) 40.9 3.2 40.2 3.4 .1360
Neoadjuvant therapy 14 (1.6%) 1 (2.8%) .449
chem/rad/both 8/5/1 1/0/0
BMI, Body mass index, PSH, positive smoking history; chem, chemother-
apy; rad, radiation; both, chemotherapy and radiation.
*Data are presented as mean  SD.
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chanical ventilation and tracheostomy was a major cause of
death and occurred more frequently in ILD patients than in
non-ILD patients. We also clarified that patients with ILD
had worse overall survival than those without ILD. This
may be because of subsequent respiratory failure due to
postoperative AIP or exacerbation of ILD. Another expla-
nation is that ILD may stimulate rapid tumor progression.
Matsushima and colleagues7 reported that lung cancers
originated in the border area of honeycombing, and they
suggested a close relationship of epithelial changes and
carcinogenesis in ILD patients. As biological characteristics
of cancer in patients with ILD are unknown, further inves-
tigation is needed on this issue.
In terms of treatment for postoperative IP, corticosteroids
are often used as a first-line treatment with regimens similar
to those in primary IPF and IP due to collagen vascular
diseases (CVD). Although results of corticosteroid treat-
ment were highly variable and optimal therapy has not been
established,8,9 rheumatoid arthritis–associated ILD ap-
peared to have a better prognosis than IPF in most studies.10
In terms of prognosis, the prognostic difference among
types of ILD after pulmonary resection is unknown. The
prognosis of IPF is generally very poor; the overall mean
survival was reported to range between 3 and 6 years.11 On
the other hand, the prognosis of IP due to CVD is relatively
better than that of IPF, but it depends on the histology.12 It
cannot be denied that ILD itself affected the prognosis of
lung cancer patients. Battafarano and colleagues13 reported
that comorbidity had a strong impact on survival in patients
with stage I non–small cell lung cancer. In this study, only
22 ILD patients could keep stable respiratory conditions
over an extended length of time. Because of such a small
number of ILD patients, we could not reach the postopera-
tive prognostic difference depending on the type of ILD,
although we have the impression that CVD-associated IP
and pneumoconiosis patients may maintain stable condi-
tions unless severe postoperative pulmonary complications
occur.
The Cox proportional hazard model revealed that ILD,
advanced pathologic stage (III and IV), male sex, high age,
and positive smoking history were the significant risk fac-
tors for long-term mortality. Except for ILD, these factors
are closely related and affect mortality. In our study, we
demonstrated that ILD exacerbated long-term survival in
addition to these other factors. Therefore, when we decide
TABLE 2. Perioperative characteristics of lung cancer patients
Characteristics Non-ILD (n  895) ILD (n  86) P value
Operation methods .216
Pneumonectomy 62 (6.9%) 0 (0%)
Lobectomy 784 (87.6%) 33 (91.7%)
Segmentectomy/partial resection 49 (5.5%) 3 (8.3%)
Tumor size (cm) (maximal diameter)* 3.5 3.4 4.5 2.7 .082
Histologic diagnoses .142
Ad/Sq/Sm/Oth 530/276/13/76 18/14/2/2
% 59.2/30.8/1.5/8.5 50/38.8/5.6/5.6
Pathologic T status .226
T1/2/3/4 349/267/96/178 8/13/7/8
% 39/29.8/10.7/19.9 22.2/36.1/19.4/22.2
Pathologic nodal status .689
N0/1/2/3 515/133/196/33 17/5/11/2
% 57.5/14.9/21.9/3.7 47.2/13.9/30.5/5.6
Pathologic staging .342
I/II/III/IV 387/118/324/48 10/4/18/3
% 43.2/13.2/36.2/5.4 27.8/11.1/50/8.3
Adjuvant therapy 177 (19.8%) 4 (11.1%) .281
(chem/rad/both) 114/61/2 4/0/0
Ad, Adenocarcinoma; Sq, squamous cell carcinoma; Sm, small cell carcinoma; Oth, other histology; chem, chemotherapy; rad, radiation; both, chemo-
therapy and radiation.
*The size was measured from the resected specimen.
TABLE 3. Postoperative respiratory complications and
mortality
Non-ILD
(n  895)
ILD
(n  36) P value
Pneumonia (%) 57 (6.4%) 6 (16.7%) .0295
IP 18 (2.0%) 9 (25%) .0001
Prolonged mech vent 27 (3.0%) 5 (13.9%) .0061
HOT 2 (0.2%) 4 (11.1%) .0001
Tracheostomy 75 (8.4%) 12 (33.3%) .0001
Scheduled 38 (50.7%) 4 (33.3%)
Emergency 37 (49.3%) 8 (66.7%)
30-day mortality 8 (0.9%) 1 (2.8%) .300
IP, Interstitial pneumonia; Prolonged mech vent, mechanical ventilation 3
days; HOT, home oxygen therapy; SVT, supraventricular tachycardia.
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operative indication for lung cancer, we should take into
account the influence of ILD and other risk factors on
prognosis.
This retrospective study has certain limitations and bi-
ases. First, only selected ILD patients who were thought to
tolerate operation were included in this study. Patients who
had severe impairment of pulmonary function were ex-
cluded from operative indication. Patients who need pneu-
monectomy or extended resection were also excluded, even
though they had permissive predicted postoperative pulmo-
nary function. This selection bias might have a significant
impact on survival. Second, there was a possibility that
incomplete or limited resection was required in some ILD
patients because of impaired pulmonary function. However,
a few limited resections were performed in the ILD group,
consistent with that in the non-ILD group. This was because
pulmonary function was relatively well preserved and lim-
ited resection was technically inadequate because of the
tumor size. Third, because an inadequate number of ILD
patients were compared with a larger number of non-ILD
patients, statistical significance may not be obtained in some
analyses.
Finally, our results suggest that a strategy for prevent-
ing postoperative IP should be established for improving
short- and long-term survival. It has been reported that
prophylactic chest physiotherapy reduced the incidence
of pulmonary complications after major abdominal sur-
gery from 27% to 6%.14 Some patients with ILD might be
responsive to steroid therapy.15 Therefore, we have been
challenging prophylactic treatment, including immediate
preoperative steroid administration, perioperative aggres-
sive pulmonary rehabilitation, and restriction of fluid admin-
istration to reduce the risk of pneumonia, lung edema, and
interstitial pneumonia.
In conclusion, ILD was a risk factor that increased post-
operative morbidity and mortality in patients with lung
cancer. Even though patients with ILD tolerated surgical
resection, the long-term survival was still lower due to
respiratory failure compared with those without ILD. Con-
sideration should be given to develop more aggressive strat-
TABLE 4. Causes of deaths
Non-ILD
(n  895)
ILD
(n  36) P value
Deaths 292 (32.6%) 21 (58.3%) 0.0020
Primary cancer 215 (73.6%) 11 (52.4%)
Respiratory failure 27 (9.3%) 7 (33.3%) 0.0028
Others 50 (17.1%) 3 (14.3%)
TABLE 5. Multivariate analysis of risk factors for overall
mortality by proportional hazard model
Variables Chi-square
Hazard
ratio 95 % CI P value
ILD 4.683 1.903 1.012-3.236 .031
Gender (male) 13.41 1.766 1.304-2.401 .0003
Age 10.57 1.015 1.008-1.027 .001
PSH 7.140 1.511 1.137-2.084 .008
Operation method 13.42 .001
Pneumonectomy 1 reference
Lobectomy 1.367 0.784 0.521-1.179 .242
Segmentectomy/
partial resection
3.052 1.649 0.941-2.892 .081
Pathologic stage 23.08 .0001
I 1 reference
II 2.854 1.244 0.966-1.602 .091
III 14.52 1.498 1.217-1.844 .0001
IV 13.76 2.573 1.561-4.238 .0002
Neoadjuvant/adjuvant
therapy
2.193 0.827 0.643-1.064 .139
CI, Confidence interval; ILD, interstitial lung disease; BMI, body mass
index; PSH, positive smoking history.
Figure 1. Overall survival after pulmonary resection for lung cancer. The 5-year survivals for the non-ILD group (n
 872, loss of 23 patient follow-up) and the ILD group (n  36) were 62.5% and 35.6%, respectively. A statistically
significant difference was found between the non-ILD and the ILD (log-rank P < .0001).
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egies for prophylactic management in patients with ILD
undergoing pulmonary resection.
We thank Ms Eri Sekine, BS, MPH (Data Management &
Biostatistics, Wyeth Lederle Japan, Tokyo, Japan) for statistical
assistance.
References
1. Tockman MS. Other host factors and lung cancer susceptibility. In:
Samet JM, editor. Epidemiology of lung cancer. New York: Marcel
Dekker; 1994. p. 397-412.
2. Hanley ME, King TE Jr, Schwarz MI, Watters LC, Shen AS, Cherniak
RM. The impact of smoking on mechanical properties of the lungs in
idiopathic pulmonary fibrosis and sarcoidosis. Am Rev Respir Dis.
1991;144:1102-6.
3. Samet JM, Humble CG, Pathak DR. Personal and family history of
respiratory disease and lung cancer risk. Am Rev Respir Dis. 1986;
134:466-70.
4. Flaherty KR, Martinez FJ. The role of pulmonary function testing in
pulmonary fibrosis. Curr Opin Pulm Med. 2000;6:404-10.
5. Martinod E, Azorin JF, Sadoun D, et al. Surgical resection of lung
cancer in patients with underlying interstitial lung disease. Ann Thorac
Surg. 2002;74:1004-7.
6. Doherty MJ, Pearson MG, O’Grady EA, Pellegrini V, Calverley PM.
Cryptogenic fibrosing alveolitis with preserved lung volumes. Thorax.
1997;52:998-1002.
7. Matsushima H, Tanaka S, Saiki Y, et al. Lung cancer associated with
usual interstitial pneumonia. Pathol Int. 1995;45:925-32.
8. Turner-Warwick M, Courtenay Evans R. Pulmonary manifestations of
rheumatoid disease. Clin Rheum Dis. 1977;3:594-604.
9. Patterson CD, Harville WE, Pierce JA. Rheumatoid lung disease. Ann
Intern Med. 1965;62:685-90.
10. Roschmann RA. Pulmonary fibrosis in rheumatoid arthritis: a review
of clinical features and therapy. Semin Arthritis Rheum. 1987;16:174-
85.
11. King TE Jr, Schwarz MI, Brown K, et al. Idiopathic pulmonary
fibrosis: relationship between histopathologic features and mortality.
Am J Respir Crit Care Med. 2001;164:1025-32.
12. Lamblin C, Bergoin C, Saelens T, Wallaert B. Interstitial lung diseases
in collagen vascular diseases. Eur Respir J Suppl. 2001;32:69s-80s.
13. Battafarano RJ, Piccirillo JF, Meyers BF, et al. Impact of comorbidity
on survival after surgical resection in patients with stage I non–small
cell lung cancer. J Thorac Cardiovasc Surg. 2002;123:280-7.
14. Fagevik Olsen M, Hahn I, Nordgren S, Lonroth H, Lundholm K.
Randomized controlled trial of prophylactic chest physiotherapy in
major abdominal surgery. Br J Surg. 1997;84:1535-8.
15. Flaherty KR, Toews GB, Lynch JP 3rd, et al. Steroids in idiopathic
pulmonary fibrosis: a prospective assessment of adverse reactions,
response to therapy, and survival. Am J Med. 2001;110:278-82.
General Thoracic Surgery Chiyo et al
1146 The Journal of Thoracic and Cardiovascular Surgery ● October 2003
G
TS
